Sonomind secures €3 million to advance its novel neuromodulation ultrasound device and opens a new therapeutic pathway in psychiatry and neurology
Summary
Sonomind raised €3 million to advance its ultrasound-based neuromodulation device for psychiatric and neurological disorders. The company secured €2 million in seed capital from Critical Path Ventures and €1 million in non-dilutive support from the French government through Bpifrance and France 2030. The funding will help Sonomind finalize development and start clinical trials for drug-resistant depression in the next few months. The company says its non-invasive system can target deep brain regions with precision and has already shown encouraging early feasibility results.
Funding
Amount
$2.4M
Total raised
Date
September 24, 2025
Announcement date
Investors
Bpifrance
Lead investors
Company
sonomind.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected